Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
MQ710‌ Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
MQ710‌ Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
MQ710‌: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
STI-5171 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
STI-5171 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
STI-5171: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
Zosurabalpin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
Zosurabalpin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Zosurabalpin: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
STRO-006 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
STRO-006 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
STRO-006: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
BnH-015B Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
BnH-015B Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
BnH-015B: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
Polyclonal Regulatory T Cell (PolyTreg) (University of Alberta) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
Polyclonal Regulatory T Cell (PolyTreg) (University of Alberta) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Polyclonal Regulatory T Cell (PolyTreg) (University of Alberta): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensin
Read →
YOLT-101 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
YOLT-101 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
YOLT-101: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
IN10028 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
IN10028 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
IN10028: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
FB-1003 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
FB-1003 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
FB-1003: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
AN-721 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
AN-721 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
AN-721: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
Choline Salicylate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
Choline Salicylate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Choline Salicylate: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
iPSC-EC(Karis Bio) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
iPSC-EC(Karis Bio) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
iPSC-EC(Karis Bio): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →